Literature DB >> 20213090

[Rheumatoid arthritis and autoimmune hemolysis: B-cell depletion for remission induction in a patient with rheumatoid arthritis and cold agglutinin disease].

P Lehmann1, W Hartung, B Ehrenstein, J Schölmerich, M Fleck.   

Abstract

Autoimmune hemolysis is a rare complication of systemic rheumatic diseases. We report on a 68-year-old female patient with established, long-standing rheumatoid arthritis, who complained of progressive weakness and worsening of her arthralgia under therapy with leflunomide. Physical and laboratory examination revealed autoimmune hemolysis due to cold agglutinin disease. As hemolysis and arthritis were refractory to steroid treatment, B-cell depletion with rituximab was performed leading to a marked reduction of hemolytic parameters as well as remission of her rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20213090     DOI: 10.1007/s00393-010-0607-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  13 in total

1.  Cold agglutinin disease--the importance of cutaneous signs.

Authors:  S Läuchli; L Widmer; S Lautenschlager
Journal:  Dermatology       Date:  2001       Impact factor: 5.366

2.  Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients.

Authors:  Claudia Schöllkopf; Lars Kjeldsen; Ole Weiss Bjerrum; Hans Torben Mourits-Andersen; Johan Lanng Nielsen; Bjarne Egelund Christensen; Bjarne Anker Jensen; Bjarne Bach Pedersen; Ellen Birkerod Taaning; Tobias Wirenfeldt Klausen; Henrik Birgens
Journal:  Leuk Lymphoma       Date:  2006-02

3.  Rituxan in the treatment of cold agglutinin disease.

Authors:  E J Lee; B Kueck
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

4.  Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease.

Authors:  S Berentsen; G E Tjønnfjord; R Brudevold; B T Gjertsen; R Langholm; E Løkkevik; J H Sørbø; E Ulvestad
Journal:  Br J Haematol       Date:  2001-10       Impact factor: 6.998

Review 5.  Red cell destruction in cold agglutinin disease.

Authors:  G Zilow; M Kirschfink; D Roelcke
Journal:  Infusionsther Transfusionsmed       Date:  1994-12

Review 6.  Activation of complement by cold agglutinins.

Authors:  M Kirschfink; K Knoblauch; D Roelcke
Journal:  Infusionsther Transfusionsmed       Date:  1994-12

7.  Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.

Authors:  Sigbjørn Berentsen; Elling Ulvestad; Ruth Langholm; Klaus Beiske; Henrik Hjorth-Hansen; Waleed Ghanima; Jon Hjalmar Sørbø; Geir E Tjønnfjord
Journal:  Haematologica       Date:  2006-04       Impact factor: 9.941

8.  Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.

Authors:  Sigbjørn Berentsen; Elling Ulvestad; Bjørn Tore Gjertsen; Henrik Hjorth-Hansen; Ruth Langholm; Håvar Knutsen; Waleed Ghanima; Fuad Victor Shammas; Geir E Tjønnfjord
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

Review 9.  Management of cold haemolytic syndrome.

Authors:  Morie A Gertz
Journal:  Br J Haematol       Date:  2007-06-11       Impact factor: 6.998

Review 10.  Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy.

Authors:  Sigbjørn Berentsen; Klaus Beiske; Geir E Tjønnfjord
Journal:  Hematology       Date:  2007-10       Impact factor: 2.269

View more
  1 in total

1.  Glucocorticoid-Responsive Cold Agglutinin Disease in a Patient with Rheumatoid Arthritis.

Authors:  Kyoko Honne; Takao Nagashima; Masahiro Iwamoto; Toyomi Kamesaki; Seiji Minota
Journal:  Case Rep Rheumatol       Date:  2015-08-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.